Most Popular
-
1
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
2
Korea’s homegrown nanosatellite successfully launches into space
-
3
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
4
Nicaragua shuts down Seoul embassy
-
5
Medical reform committee kicks off despite boycott from doctors
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
Hybe's multilabel system tested amid conflict with Ador
-
7
SNU profs to suspend treatment for one day
-
8
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
9
SK hynix pledges W20tr to ramp up DRAM production at home
-
10
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
Ahn-gook Pharm to apply for diabetes treatment clinical trials in Europe
By 황유미Published : Aug. 17, 2016 - 16:59
[THE INVESTOR] Ahn-gook Pharmaceutical announced on Aug. 17 that it has completed a nonclinical study on UAI-101, an 11B-HSD1 inhibitor, and will apply for phase 1 clinical trials to the European Medicines Agency by the end of this year.
This new drug candidate is a new type of therapy that will selectively inhibit 11B-HSD1, an enzyme that controls cortisol that regulates metabolism and thus can cause metabolic-related conditions including diabetes, obesity and dyslipidemia.
This new drug candidate is a new type of therapy that will selectively inhibit 11B-HSD1, an enzyme that controls cortisol that regulates metabolism and thus can cause metabolic-related conditions including diabetes, obesity and dyslipidemia.
Unlike existing treatments, however, it does not have side effects such as cardiovascular disease or weight gain, according to the company.
By Hwang You-mee (glamazon@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/25/20240425050656_0.jpg&u=)
